Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation.
Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation.
复制标题
DOI：
10.3389/fpubh.2017.00110
复制
发表时间：
2017
影响因子：
5.2
通讯作者：
McDevitt JT
中科院分区：
文献类型：
--
作者：
Christodoulides NJ;McRae MP;Abram TJ;Simmons GW;McDevitt JT
缺乏标准的工具和方法以及缺乏精简的多标记物批准程序阻碍了新生物标记物转化为临床实践的速度，这些生物标记物用于治疗折磨人类的各种疾病。具有卓越分析性能和降低试剂成本的先进新技术，如本文介绍的可编程生物纳米芯片系统，有可能改变医疗保健的提供方式。这个通用平台系统具有数字化生物学的能力，从而产生具有学习能力的传感器模式。有了精心规划的设备设计、开发和分销计划，就有机会将基因组学、蛋白质组学、代谢组学和糖组学领域的基础发现转化为可操作的特征，从而使医生和患者能够更好地管理医疗保健。虽然这个过程很复杂，需要一些时间，但这里展示了这一灵活平台的三个应用领域，该平台将生物标志物内容与微创或非侵入性采样相结合，例如用于口腔癌风险评估的刷活检；血清、血浆和小容量血液用于评估心脏风险和健康；并在需要时进行口服液取样以进行药物滥用测试。
The lack of standard tools and methodologies and the absence of a streamlined multimarker approval process have hindered the translation rate of new biomarkers into clinical practice for a variety of diseases afflicting humankind. Advanced novel technologies with superior analytical performance and reduced reagent costs, like the programmable bio-nano-chip system featured in this article, have potential to change the delivery of healthcare. This universal platform system has the capacity to digitize biology, resulting in a sensor modality with a capacity to learn. With well-planned device design, development, and distribution plans, there is an opportunity to translate benchtop discoveries in the genomics, proteomics, metabolomics, and glycomics fields by transforming the information content of key biomarkers into actionable signatures that can empower physicians and patients for a better management of healthcare. While the process is complicated and will take some time, showcased here are three application areas for this flexible platform that combines biomarker content with minimally invasive or non-invasive sampling, such as brush biopsy for oral cancer risk assessment; serum, plasma, and small volumes of blood for the assessment of cardiac risk and wellness; and oral fluid sampling for drugs of abuse testing at the point of need.